China’s inactivated Sinopharm COVID-19 jab has been used in 50 countries and regions, the National Health Commission (NHC) said at a media conference on Sunday.
Sinopharm's Phase III clinical trials have involved 125 countries and regions, and the vaccine has received emergency use authorization in more than 190 countries and regions.
“The large vaccinated sample size and widespread use of Sinopharm’s COVID-19 vaccine fully demonstrate that it’s effective against a variety of pathogenic factors,” said Zhang Yuntao, vice president of Sinopharm.
Over 100 million COVID-19 vaccinations were administered in China as of March 27, according to the NHC.
China is vigorously promoting COVID-19 vaccination campaign. "It is hoped that by the end of 2021, China can achieve 70-80 percent coverage of vaccination, basically achieving herd immunity," said Gao Fu, director of the Chinese Center for Disease Control and Prevention.
(Compiled by Ruan Ziyan)